Last reviewed · How we verify

SP-102 — Competitive Intelligence Brief

SP-102 (SP-102) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cannabinoid. Area: Pain.

phase 3 cannabinoid CB1 receptor Pain Small molecule Live · refreshed every 30 min

Target snapshot

SP-102 (SP-102) — Scilex Pharmaceuticals, Inc.. SP-102 is a synthetic version of delta-9-tetrahydrocannabinol (THC), the primary psychoactive compound in cannabis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
SP-102 TARGET SP-102 Scilex Pharmaceuticals, Inc. phase 3 cannabinoid CB1 receptor
Cannabis oil Cannabis oil Assaf-Harofeh Medical Center marketed Phytocannabinoid preparation CB1 receptor, CB2 receptor
Cannabis Sativa Oil Cannabis Sativa Oil Fondation pour l'accueil et l'hébérement des personnes âgées marketed Phytocannabinoid preparation CB1 receptor, CB2 receptor
MediCabilis CBD Oil MediCabilis CBD Oil Gold Coast Hospital and Health Service marketed Cannabinoid CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor (multiple targets)
Cannabis Extract Oil SR Capsule Cannabis Extract Oil SR Capsule University of Sao Paulo General Hospital marketed Cannabinoid receptor modulator CB1 receptor, CB2 receptor
Hemp Hemp Thammasat University Hospital marketed Phytocannabinoid preparation CB1 receptor, CB2 receptor, TRPV1, 5-HT1A receptor
Dronabinol Capsules Dronabinol Capsules Montefiore Medical Center phase 3 Cannabinoid receptor agonist CB1 receptor, CB2 receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cannabinoid class)

  1. Aphios · 1 drug in this class
  2. Azienda Ospedaliera Universitaria Policlinico "G. Martino" · 1 drug in this class
  3. Scilex Pharmaceuticals, Inc. · 1 drug in this class
  4. Wolfson Medical Center · 1 drug in this class
  5. Zynerba Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SP-102 — Competitive Intelligence Brief. https://druglandscape.com/ci/sp-102. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: